Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Lonza Group Ltd ( (CH:LONN) ) is now available.
Lonza Group Ltd has announced the nomination of Claudia Süssmuth-Dyckerhoff as an Independent Member of the Board, subject to shareholder approval at the 2026 AGM. Claudia is set to become Vice-Chair of the Board and a member of the Remuneration Committee, bringing extensive international experience in healthcare and life sciences. This nomination is part of Lonza’s strategic succession planning, as current board members Jürgen Steinemann and Barbara Richmond will not seek re-election due to reaching their maximum tenures. The changes reflect Lonza’s commitment to robust governance and continuity in leadership, with Marion Helmes set to succeed Barbara Richmond as Chair of the Audit and Compliance Committee.
The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF670.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. The company collaborates with pharmaceutical and biotech companies globally to transform innovative ideas into viable therapies, focusing on life-saving and life-enhancing treatments. Lonza operates across five continents with a workforce of over 19,000 employees and reported sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in the first half of 2025.
Average Trading Volume: 109,271
Technical Sentiment Signal: Sell
Current Market Cap: CHF36.53B
Learn more about LONN stock on TipRanks’ Stock Analysis page.